Osaikang Pharmaceuticals injected with nida platinum through a consistent evaluation

Nida platinum is a cisplatin similar, suitable for head and neck cancer, small cell carcinoma, non-small cell lung cancer, esophageal cancer, ovarian cancer and other solid tumors, there are currently 4 domestic enterprises have injection of Nida platinum production approval.
meters of intranet data show that in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal injection sales of more than 700 million yuan, the growth rate has declined.
2020H1 China's public medical institutions terminal injection Nida platinum manufacturers competition pattern Source: Minet China's public medical institutions terminal competition pattern in the first half of 2020 China's public medical institutions terminal injection Nida platinum manufacturers competition pattern, Osaikang with 35.96 percent market share leading, the first through a consistent evaluation, to help consolidate the market.
Injection Nida platinum consistency evaluation in review Source: Mienet consistency evaluation database in addition to Osaikang, qilu, Nanjing Synth Dongyuan pharmaceutical two enterprises submitted injection nida platinum consistency evaluation supplementary application, is still in the "in the review and approval (in the drug review center)" state.
Osaikang has been evaluated injection Source: Minet MED2.0 China Drug Review Database Minet data show that at present, Osaikang has 7 injections through or as consistent evaluation, injection with Nida platinum is the company's 2nd over-rated anti-tumor injection, is also the first anti-tumor injection by supplementary application.
sources: Mi Net database, the Official Website of the State Drug Administration, etc. Note: data statistics as of January 25, if there are omissions, welcome to point out!